- Home
- Publications
- Publication Search
- Publication Details
Title
Panobinostat: First Global Approval
Authors
Keywords
Multiple Myeloma, Bortezomib, Lenalidomide, Myelofibrosis, Azacitidine
Journal
DRUGS
Volume 75, Issue 6, Pages 695-704
Publisher
Springer Nature
Online
2015-04-03
DOI
10.1007/s40265-015-0388-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
- (2014) S Bauer et al. BRITISH JOURNAL OF CANCER
- A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function
- (2014) Marije Slingerland et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors
- (2014) J. E. Gray et al. CLINICAL CANCER RESEARCH
- Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
- (2014) Sridurga Mithraprabhu et al. Epigenetics
- 572 Oral panobinostat in patients with advanced tumors and impaired renal function: Relationship between pharmacokinetics and key safety parameters
- (2014) M. Porro et al. EUROPEAN JOURNAL OF CANCER
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma
- (2013) James R. Berenson et al. ANNALS OF HEMATOLOGY
- Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenstrom macroglobulinemia
- (2013) I. M. Ghobrial et al. BLOOD
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
- (2013) P A Cassier et al. BRITISH JOURNAL OF CANCER
- Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis
- (2013) Daniel J. DeAngelo et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)
- (2013) John Mascarenhas et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer
- (2013) Dana E. Rathkopf et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Reducing TNF Receptor 2 + Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients
- (2013) Chindu Govindaraj et al. CLINICAL CANCER RESEARCH
- A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors
- (2013) Sunil Sharma et al. INVESTIGATIONAL NEW DRUGS
- Phase Ib Study of Panobinostat and Bortezomib in Relapsed or Relapsed and Refractory Multiple Myeloma
- (2013) Jesús F. San-Miguel et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer
- (2013) Filippo de Marinis et al. Journal of Thoracic Oncology
- Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies
- (2013) D J DeAngelo et al. LEUKEMIA
- Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
- (2013) U Platzbecker et al. LEUKEMIA
- Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
- (2012) John H. Strickler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients
- (2012) Sally Clive et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors
- (2012) Suzanne F. Jones et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
- (2012) Akira Fukutomi et al. INVESTIGATIONAL NEW DRUGS
- Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma
- (2012) Massimo Offidani et al. LEUKEMIA & LYMPHOMA
- Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome
- (2011) Sophie Dimicoli et al. AMERICAN JOURNAL OF HEMATOLOGY
- The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer
- (2011) Geoffrey I. Shapiro et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma
- (2011) John D. Hainsworth et al. CANCER INVESTIGATION
- Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors
- (2011) Sachi Morita et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma
- (2011) J. Drappatz et al. JOURNAL OF NEURO-ONCOLOGY
- Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
- (2011) T. Hideshima et al. MOLECULAR CANCER THERAPEUTICS
- A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer
- (2010) Dana Rathkopf et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients
- (2010) Evangelos Terpos LEUKEMIA RESEARCH
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
- (2009) Peter Atadja CANCER LETTERS
- High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model
- (2009) G. Floris et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation